Apollomics Inc. (APLM)

Market Cap	68.75M
Revenue (ttm)	n/a
Net Income (ttm)	-240.81M
Shares Out	13.43M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,378
Open	5.43
Previous Close	5.54
Day's Range	5.12 - 5.58
52-Week Range	3.71 - 49.00
Beta	n/a
Analysts	Strong Buy
Price Target	21.50 (+304.9%)
Earnings Date	Aug 3, 2023

About APLM

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. T...

• Industry: Biotechnology & Medical Research
• Sector: Healthcare
• Founded: 2016
• Employees: 43
• Stock Exchange: NASDAQ
• Ticker Symbol: APLM

Analyst Forecast

According to 2 analysts, the average rating for APLM stock is "Strong Buy." The 12-month stock price forecast is $21.5, which is an increase of 304.90% from the latest price.

Price Target

$21.5

(304.90% upside)

Analyst Consensus: Strong Buy